Home Pilots GrayMatters Health receives FDA 510(k) for PTSD neuromodulation therapy Pilots GrayMatters Health receives FDA 510(k) for PTSD neuromodulation therapy By - March 27, 2023 53 0 Facebook Twitter Pinterest WhatsApp The company’s product, Prism, uses neurofeedback to help PTSD patients learn to control their emotional response. RELATED ARTICLESMORE FROM AUTHOR Pilots Medtronic issues voluntary recall of MiniMed insulin pumps Pilots Hybrid primary care company Rezilient Health scores $10M Pilots Empathy Health Technologies raises $2.8M for Sober Sidekick app LEAVE A REPLY Cancel reply Please enter your comment! Please enter your name here You have entered an incorrect email address! Please enter your email address here Save my name, email, and website in this browser for the next time I comment. FOLLOW ME0FansLike0FollowersFollow0SubscribersSubscribe POPULAR ARTICLES Endoscopic AI maker AI Medical Service scores $70M in Series C funding Pilots - April 29, 2022 0 Insulet announces another asset acquisition and more digital health news Pilots - February 15, 2023 0 Aevice targets Japan, US with latest $1M fund and more briefs Pilots - May 23, 2024 0 Study: VR therapeutic reduces pain intensity long term, compared with sham app Pilots - May 27, 2022 0 Indian EMR startup HealthPlix scores $22M in Series C funding Pilots - March 15, 2023 0 POPULAR CATEGORIESPilots2166Applications750Testing283Collaborations15GitHub3